298 related articles for article (PubMed ID: 32767003)
1. Capturing the Magic Bullet: Pharmacokinetic Principles and Modeling of Antibody-Drug Conjugates.
Zuo P
AAPS J; 2020 Aug; 22(5):105. PubMed ID: 32767003
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic considerations for antibody drug conjugates.
Lin K; Tibbitts J
Pharm Res; 2012 Sep; 29(9):2354-66. PubMed ID: 22740180
[TBL] [Abstract][Full Text] [Related]
3. Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.
Singh AP; Shin YG; Shah DK
Pharm Res; 2015 Nov; 32(11):3508-25. PubMed ID: 25666843
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies.
Li C; Zhang C; Li Z; Samineni D; Lu D; Wang B; Chen SC; Zhang R; Agarwal P; Fine BM; Girish S
MAbs; 2020; 12(1):1699768. PubMed ID: 31852341
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells.
Sharma S; Li Z; Bussing D; Shah DK
Drug Metab Dispos; 2020 May; 48(5):368-377. PubMed ID: 32086295
[TBL] [Abstract][Full Text] [Related]
6. Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes.
Abdollahpour-Alitappeh M; Lotfinia M; Gharibi T; Mardaneh J; Farhadihosseinabadi B; Larki P; Faghfourian B; Sepehr KS; Abbaszadeh-Goudarzi K; Abbaszadeh-Goudarzi G; Johari B; Zali MR; Bagheri N
J Cell Physiol; 2019 May; 234(5):5628-5642. PubMed ID: 30478951
[TBL] [Abstract][Full Text] [Related]
7. Antibody-drug conjugates for cancer.
Chau CH; Steeg PS; Figg WD
Lancet; 2019 Aug; 394(10200):793-804. PubMed ID: 31478503
[TBL] [Abstract][Full Text] [Related]
8. Antibody-Drug Conjugates for Breast Cancer.
Marmé F
Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
[TBL] [Abstract][Full Text] [Related]
9. Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics.
Sukumaran S; Zhang C; Leipold DD; Saad OM; Xu K; Gadkar K; Samineni D; Wang B; Milojic-Blair M; Carrasco-Triguero M; Rubinfeld B; Fielder P; Lin K; Ramanujan S
AAPS J; 2017 Jan; 19(1):130-140. PubMed ID: 27679517
[TBL] [Abstract][Full Text] [Related]
10. Establishing in vitro-in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach.
Shah DK; Loganzo F; Haddish-Berhane N; Musto S; Wald HS; Barletta F; Lucas J; Clark T; Hansel S; Betts A
J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):339-349. PubMed ID: 29423862
[TBL] [Abstract][Full Text] [Related]
11. Cysteine-Based Coupling: Challenges and Solutions.
You J; Zhang J; Wang J; Jin M
Bioconjug Chem; 2021 Aug; 32(8):1525-1534. PubMed ID: 34105345
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates.
Kamath AV; Iyer S
Pharm Res; 2015 Nov; 32(11):3470-9. PubMed ID: 25446773
[TBL] [Abstract][Full Text] [Related]
13. Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
Kågedal M; Gibiansky L; Xu J; Wang X; Samineni D; Chen SC; Lu D; Agarwal P; Wang B; Saad O; Koppada N; Fine BM; Jin JY; Girish S; Li C
J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):537-548. PubMed ID: 28918591
[TBL] [Abstract][Full Text] [Related]
14. An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens.
Menezes B; Cilliers C; Wessler T; Thurber GM; Linderman JJ
AAPS J; 2020 Jan; 22(2):29. PubMed ID: 31942650
[TBL] [Abstract][Full Text] [Related]
15. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and ADME characterizations of antibody-drug conjugates.
Lin K; Tibbitts J; Shen BQ
Methods Mol Biol; 2013; 1045():117-31. PubMed ID: 23913144
[TBL] [Abstract][Full Text] [Related]
17. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
Tsuchikama K
Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
[TBL] [Abstract][Full Text] [Related]
18. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology.
Liu SN; Li C
Cancer Chemother Pharmacol; 2021 Jun; 87(6):743-765. PubMed ID: 33792763
[TBL] [Abstract][Full Text] [Related]
20. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.
Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K
Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
